Clinical Trials Logo

Mobility Limitation clinical trials

View clinical trials related to Mobility Limitation.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06446414 Enrolling by invitation - Aging Clinical Trials

Evaluating Implementation and Impact of Provincial Scale-up of the Adapted Choose to Move (CTM) Program

Start date: June 2024
Phase: N/A
Study type: Interventional

Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. In this project, the investigators will support community-based seniors' services (CBSS) organizations across BC through a readiness-building process so they can adapt CTM and deliver the program to more diverse groups of underserved older adults than have previously participated in CTM.

NCT ID: NCT06434298 Enrolling by invitation - Aging Clinical Trials

Provincial Scale-up of Choose to Move (CTM) Phase 4

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. In this project, the investigators will expand delivery of the optimized Phase 4 program with large and small partner organizations and will describe and assess scale-up, implementation, and impact of CTM Phase 4.

NCT ID: NCT06252259 Enrolling by invitation - Aging Clinical Trials

Evaluating Implementation and Impact of the Adapted Choose to Move (CTM) Program

CTM
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. In Phase 5, the goal of CTM is to enhance physical activity, mobility and social connectedness in three target populations: South Asian older adults, older men, and older adults living in Northern BC. To do so, the investigators will support community-based seniors' services (CBSS) organizations through a readiness-building process so they can adapt CTM and deliver the program to these populations. This study has two main research questions: 1. How are adapted CTM programs delivered ('implementation outcomes') and what factors influence delivery ('implementation determinants')? 2. What is the impact of the adapted CTM programs on health outcomes of older adults?

NCT ID: NCT05736484 Enrolling by invitation - Hypertension Clinical Trials

Randomized Clinical Trial to Improve Mobility After Hospitalization

MOVE_ON
Start date: September 19, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to test the feasibility of using behavioral economic interventions (gamification with social incentives) to increase physical activity after hospital discharge to reduce incident mobility disability among older adults.

NCT ID: NCT05447299 Enrolling by invitation - Cerebral Palsy Clinical Trials

Neuromusculoskeletal Modeling of Muscle Spasticity

Start date: January 15, 2019
Phase:
Study type: Observational

Cerebral palsy (CP) is a movement and posture disorder caused by an injury to the developing brain, with a prevalence in Sweden of about 2/1000 live births. Children with CP have walking difficulties, and decreased muscle mass and muscle function as compared to typically developing (TD) children. The extent of disability in CP depends on the severity and timing of the primary cerebral lesion and can be classified with the gross motor function classification system (GMFCS E&R) that ranges from walking without limitations (I) to being transported in a wheelchair (V). Muscle function commonly deteriorates with age and contracture development is often clinically evident as early as at 4 years of age. In addition to being thinner and weaker, skeletal muscle in children with CP develop poor quality, i.e., increasingly higher amounts of fat and connective tissue at the expense of functional, contractile proteins. How long-term standard treatments for children with spastic CP including, training and orthotics use, with botulinum toxin (BoNT-A) treatment as an adjunct, affects muscle on functional, structural, and microscopic level in CP has not yet been published. Therefore, we will investigate the muscle function as well as functional mobility, structure, and spasticity. We will conduct functional mobility tests. Muscle strength will be measured with a rig-fixed dynamometer, and muscle structure will be measured with magnetic resonance imaging. The spasticity will be instrumentally assessed by the NeuroflexorTM, a machine measuring resistance in a muscle when a pedal is passively moving the participants foot at two different speeds. We will follow participants, for 1 year, with 4 measurements during this period. In order to better treat these children, we need to better understand the complex, interrelated interactions of musculoskeletal properties and function in children with CP. Our hypothesis is that muscle structure and function is affected by standard clinical treatments sessions including routine botulinum toxin treatment. Analyzing the effect of standard care may help planning of more effective clinical treatments in the future.